Boston Scientific announced a definitive agreement to acquire medtech firm Penumbra in a deal valued at approximately $14.5 billion, marking the company's largest acquisition in two decades. The transaction is expected to be completed in 2026 and will significantly expand Boston Scientific's cardiovascular device portfolio...
Bullish Signals
Acquired Penumbra for $14.5 billion, largest deal in two decades.
Raised annual profit forecast due to robust heart device demand.
Shares jumped 13% to $354.70 in premarket trading.
Penumbra expected to contribute $1.4 billion in sales in 2025.
Deal expands capabilities in treating stroke and pulmonary embolism.
Boston Scientific (BSX) shares have declined significantly in 2026, dropping over 52% from their September 2025 peak to close at $51.83 on August 14, 2026. Despite this price action, the company's fundamental financial performance remains robust, with Q2 net sales rising 7.5% to $5.442bn and...
Bullish Signals
Q2 adjusted EPS of $0.86 beat the company's own guidance range of $0.82β$0.84, demonstrating strong execution despite market headwinds.
Gross margins expanded significantly by 305 basis points to reach 70.7%, indicating strong pricing power and operational efficiency.
Operating income surged 43.8% to $1.178bn, reflecting robust underlying profitability even as revenue growth moderates.
International markets are driving double-digit growth for key franchises like Watchman (20%) and electrophysiology (23%), providing a stable revenue base.
The company is retiring shares, reducing the diluted count by 1.3% while accumulating cash to fund its strategic Penumbra acquisition.
Analyst consensus remains overwhelmingly positive with 26 out of 29 analysts rating the stock as a buy, signaling confidence in long-term value.
Bearish Signals
US revenue for flagship franchises Watchman and electrophysiology has stalled, growing only 2.9% and 3.2% respectively compared to over 20% international growth.
The stock price has fallen 52.1% from its peak as the market re-prices expectations from high-growth multiples to a mature 15.7x earnings multiple.
Management signaled that Watchman revenue would be roughly flat sequentially, triggering a significant sell-off in May 2026.
The massive $14.5bn acquisition of Penumbra has strained the balance sheet, reducing cash reserves and increasing debt obligations significantly.
US markets for pulsed-field ablation and left-atrial-appendage closure are facing saturation, limiting future organic growth potential in the company's highest-margin segments.
Equitable Trust Co. established a new position in Boston Scientific Corporation (BSX) during the first quarter by purchasing 12,912 shares valued at approximately $810,000. Several other institutional investors also increased their stakes, including Whipplewood Advisors LLC, which boosted its holdings by over 1,700%, and Resona...
The U.S. Food and Drug Administration issued a warning letter to Boston Scientific on Tuesday, August 23, 2005, citing "serious regulatory problems" at the company's medical device distribution plant in Massachusetts. The FDA specifically noted that heart stents were shipped to hospitals despite identified quality...
Bullish Signals
Company actively addressing all FDA letter points.
Corrective actions completed in many regulatory areas.
No shipment problems harmed patients per management.
Recalled 100,000 Taxus stents; defect now fixed.
Bearish Signals
FDA warned Boston Scientific over serious regulatory problems at MA plant.
S&P Global Ratings has revised Boston Scientific's credit outlook to negative while affirming its A- issuer and senior unsecured debt ratings. This downgrade reflects increased pressure on key business segments, specifically the WATCHMAN left atrial appendage closure franchise and the electrophysiology division, which together account...
Bullish Signals
Penumbra acquisition adds $1.4B 2025 revenue.
Diversified portfolio offsets franchise weakness.
Bearish Signals
S&P downgraded outlook due to weak Q3 results and lower 2026 guidance.
Clinical trial resultsDevice clearanceNew AI featuresAI-generated analysis
Boston Scientific reported third-quarter net sales of USD 5.138 billion, representing a 1.5% increase on reported, operational, and organic bases compared to the prior year. The company delivered adjusted earnings per share of USD 0.73 and GAAP earnings per share of USD 0.40, contrasting with...
Bullish Signals
Q3 net sales rose 1.5% to USD 5.138 billion.
Bearish Signals
Q4 sales expected to drop 1-3% due to cyber disruptions.
Revenue pressured by ongoing cybersecurity operational challenges.
Boston Scientific (BSX) stock fell 2.3% in premarket trading after the company formally warned it is unlikely to meet its net sales growth and adjusted EPS guidance for both Q3 and full-year 2026. This revised stance follows a cyberattack disclosed on August 25, which has...
Bullish Signals
No evidence found of ongoing unauthorized access to systems.
Bearish Signals
Warned unlikely to meet Q3/2026 sales/EPS guidance due to cyberattack.
On July 21, 2026, Boston Scientific Corporation announced a major global restructuring initiative approved by its Board of Directors, aimed at improving cost efficiency and advancing strategic growth objectives. The company estimates total pre-tax charges between $700 million and $800 million for the program, which...
Bullish Signals
Restructuring delivers $500M annual pre-tax savings by 2029.
Reinvesting savings into strategic growth initiatives strengthens positioning.
Bearish Signals
Pre-tax charges range from $700M to $800M.
Termination benefits estimated between $275M and $300M.
Medical device manufacturer Boston Scientific (BSX) disclosed on Wednesday that it is currently suffering from an active cyberattack that is significantly disrupting its operations. The company stated in an SEC filing that the incident has compromised access to critical information systems and applications, specifically hindering...
Bearish Signals
Boston Scientific disclosed an active cyberattack disrupting operations and access to critical information systems and applications.
The company confirmed it is unable to process and ship orders, which will likely adversely impact sales revenue.
Analysts at Piper Sandler warn that the inability to ship products poses a significant risk to a company already facing slowing sales growth.
The cyberattack adds to existing pressure on the stock, which has already fallen nearly 50% year-to-date following weak profit forecasts.
Aristotle Atlantic Partners LLC increased its stake in Boston Scientific Corporation (NYSE: BSX) by 5.9% during the first quarter, purchasing an additional 12,480 shares to hold a total position of 223,520 shares valued at $14.026 million. Other institutional investors also adjusted their positions, with FWL...
Bullish Signals
$5B buyback authorization signals undervaluation.
Insiders bought $328K in May.
Major firms maintain Buy/Outperform ratings.
Low PEG ratio of 0.85.
Bearish Signals
Analysts lowered targets: Stifel $75 to $65, Truist $64 to $62.
Stock trades below 50-day ($47.21) and 200-day ($64.06) moving averages.
Assetmark Inc. increased its stake in Boston Scientific Corporation (NYSE: BSX) by 36.9% during the first quarter, purchasing an additional 39,270 shares to hold a total of 145,679 shares valued at $9.14 million. Several other institutional investors also adjusted their positions, including new stakes from...
Bullish Signals
Company announced $5B share repurchase program.
Assetmark increased position by 36.9%.
Bangor Savings Bank grew stake 94.7%.
Quick ratio of 1.22 and current ratio 1.90.
Insiders bought 9,800 shares worth $554k.
Bearish Signals
Downgraded to peer perform by Wolfe Research on May 29th.
Price target lowered from $75.00 to $65.00 by Stifel Nicolaus.
Trading below 50-day average of $47.99 and 200-day average of $65.29.
Bancreek Capital Management LP increased its stake in Boston Scientific Corporation (NYSE: BSX) by purchasing 39,000 shares worth approximately $2.45 million during the first quarter, making the stock its sixth-largest holding at 10.6%. Several other institutional investors also adjusted their positions, with Frazier Financial Advisors...
Bullish Signals
Revenue hit $5.20 billion, beating estimates by $10 million.
Earnings per share reached $0.80, surpassing the $0.79 consensus.
Management authorized a new $5.00 billion stock repurchase plan.
Revenue grew 11.6% year-over-year to $5.20 billion this quarter.
Insiders bought over $980,000 of stock in the last 90 days.
Institutional investors have made mixed moves regarding Boston Scientific Corporation (NYSE:BSX) in recent quarters. Bleakley Financial Group LLC significantly reduced its stake by 51.3% in the first quarter, selling over 45,000 shares. Conversely, several other funds increased their positions; Ieq Capital LLC raised holdings by...
Bullish Signals
Beat Q1 EPS estimates at $0.80 versus $0.79 consensus.
Revenue grew 11.6% YoY to $5.20 billion.
Secured new $5.00 billion stock buyback authorization.
Ieq Capital increased stake by 97.0% in Q2.
Insiders bought $554,012 worth of stock in May.
Maintains strong net margin of 17.29% and ROE of 19.17%.
Bearish Signals
Wells Fargo cut target to $55 from $75 due to valuation.
Barclays lowered target to $89 from $96 despite overweight rating.
Weiss Ratings downgraded stock from hold to sell in early July.
DSM Capital Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 11,846.4% in the first quarter, purchasing an additional 559,625 shares to hold a total of 564,349 shares valued at $35.4 million. Other institutional investors also adjusted their positions, with Ieq Capital...
Bullish Signals
DSM Capital increased position by 11,846.4%, adding over half a million shares.
Revenue beat expectations with $5.20 billion sales, up 11.6% year-over-year.
Earnings exceeded estimates at $0.80 EPS versus $0.79 consensus.
Management launched $5.00 billion buyback program for up to 6.4% of shares.
Insiders bought nearly $554,000 worth of stock last quarter.
Bearish Signals
Analyst Citigroup cut price target from $87.00 to $70.00.
Wall Street Zen and Daiwa downgraded ratings to hold.
BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 45.1% during the first quarter, selling 58,923 shares to hold a remaining position of 71,593 shares valued at approximately $4.49 million. While this major institutional holder trimmed its exposure,...
Bullish Signals
Beat Q1 EPS estimates at $0.80 vs $0.79 consensus.
Banque Transatlantique SA increased its stake in Boston Scientific Corporation (NYSE:BSX) by 13.0% during the fourth quarter, purchasing an additional 139,431 shares to own a total of 1,211,331 shares valued at $115.46 million. This position represents 2.8% of the bank's portfolio and marks it as...
S&P Global Ratings has revised Boston Scientific's credit outlook to negative from stable, citing weakening growth in its WATCHMAN and electrophysiology franchises. The agency affirmed the company's A- issuer rating but highlighted concerns over pressure on these two key business segments which have historically driven...
Bearish Signals
S&P downgraded credit outlook to negative due to franchise pressure.
Boston Scientific reported its third-quarter 2026 results on October 28, providing an operational update for investors ahead of the new month. The company maintained focus on execution across its medical-device portfolio while releasing key financial and strategic developments. On November 2, the company announced that...
Bullish Signals
Boston Scientific met primary endpoints for SIMPLAAFY study on Nov 2.
Blackstone Life Sciences (BXLS) has announced a $455 million strategic collaboration with Boston Scientific Corp. to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. This partnership marks the first instance where Blackstone Life Sciences and Boston Scientific will jointly fund...
Bullish Signals
Secured $455M collaboration for VITALYST system development.
First joint funding signals strong confidence in technology.
Addresses unmet needs in acute myocardial infarction shock.
This article compares the financial outlook and operational metrics of Boston Scientific (BSX) and Becton Dickinson (BDX), focusing on recent guidance changes and market positioning. Boston Scientific has lowered its fiscal 2026 revenue growth forecast to a midpoint of 6.0% due to a sharp slowdown...
Bullish Signals
Operating margin hit 21.0%, beating Becton Dickinson's 14.4%.
Revenue grew 16.2% vs competitor's 7.1% over three periods.
Bearish Signals
2026 revenue growth forecast lowered to 6.0% midpoint.
Cyberattack impacts Q3 and full-year 2026 results.
Operating margins pressured in 2027 by product mix.
WATCHMAN market slowed; rivals gain electrophysiology share.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)